Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Breaking Down Silos. Connecting Expertise. Accelerating Patient Impact.

Biomarkers & CDx Programme at Precision Medicine Europe

30 November - 01 December 2027
Congress Centre Basel, Basel, Switzerland

The Biomarkers & CDx programme covers the path from biomarker discovery and validation to companion diagnostics that reach patients. It is for translational and clinical biomarker leads, CDx developers, and regulatory and market access teams.

Session Themes

Which biomarkers will reach patients, and what will it take to get them approved and paid for? Sessions follow the biomarker from early evidence to clinical use, alongside the diagnostics, data and regulatory decisions it depends on. Session themes include:

Biomarkers in Translational & Clinical Development
How biomarkers are identified, validated and applied to guide patient stratification, treatment selection and personalised therapeutic strategies.

Tools & Technologies for Biomarker Analysis
How liquid biopsies, genomic tools and other emerging technologies are improving biomarker detection, analysis and interpretation.

Biomarkers for Clinical Trials & Personalised Patient Treatment
Using biomarkers to design better trials, stratify patients and predict treatment response.

Companion Diagnostics & Regulations
How companion diagnostics are developed, validated and regulated to support targeted therapies.

Featured Sessions

IVDR Regulations & Their Impact (panel) · AI-Enabled Clinical Trial Innovation: From Biomarker Data to Decisions (panel) · Proteomic Innovations to Drive Discovery · The Future of Liquid Biopsy: Emerging Technologies, Clinical Translation & Cross-Sector Collaboration

Biomarkers & CDx in Basel

Building on two decades of Biomarkers in Europe, and hosted in Basel for the second time, the Biomarkers & CDx programme at Precision Medicine Europe draws on a multinational community of researchers, industry leaders and healthcare organisations working towards personalised therapies, supported by tailored biomarkers and diagnostics.

Basel Skyline

What's changed this year

Between October 2025 and October 2026, biomarker research advanced in five areas: AI-driven discovery, liquid biopsies for cancer detection and monitoring, multi-omics integration, non-invasive testing and stronger clinical validation. Blood-based biomarkers are opening the way to earlier diagnosis and ongoing monitoring. The challenge now is reproducibility, standardisation and showing clinical benefit before routine use.

Who should attend

Translational and clinical biomarker leads

CDx developers 

Regulatory and market access teams 

Diagnostics companies 

Clinicians

Clinical trial experts 

Biomarker analysis teams

Biomarkers CDx Who Should Attend Image-2

Featured Speakers from Biomarkers 2026

Adisa Trnjanin
Co-Founder & Co-Head,
ZHAW Life Sciences
Aditi Deshpande
Director, Biology,
Bioage labs
Alberto Valdeolivas Urbelz
Principal Scientist,
Roche
Amela Jusic
Translational Research Lead,
Quant Biomarkers
Bernhard Polzer
Head of Cellular and Molecular Diagnostics,
Fraunhofer Institute
Bogdan Munteanu
Lab Head Global Imaging Mass Spectrometry Biomarker Discovery Platform (DMPK),
Sanofi
Carsten Krantz
Associate Director,
Novartis
Catherine Gilbert
Field Application Scientist,
Seer
Céline Pallaud
Precision Medicine Strategy Head,
Novartis
Celine Vandamme
Director, Scientific Business Development,
CellCarta
David Klug
Professor of Chemical Biophysics, Department of Chemistry,
Imperial College London
David Latto
Associate Product Specialist Director ,
IQVIA Laboratories
Show More Speakers
Hide Speakers
Diego Saldana Miranda
Associate Director and Senior Data Scientist,
Novartis
Emmanouil Karteris
Professor in Biomedical Sciences,
Brunel University of London
Enchi Liu
Vice President & Head Experimental Medicine,
Lundbeck
Eric Letouzé
Head of Single Cell,
One Biosciences
Eshita Mutt
Bioinformatics Support Scientist,
Illumina
Eshita Mutt,
Global Head of Scientific Strategies,
StratifAI
Espen Walker
Head of Global Medical Diagnostics,
AstraZeneca
Federico Pratesi
Senior Multiomics Sales Specialist,
Illumina
Florian Langer
Sales & Applications Manager,
Histomography GmbH
Gavin Gordon
SVP, Precision Medicine & Strategic Alliances,
Singular Genomics
Georgia Cresswell
Research Services Business Development Manager,
Patholytix
Guillaume Cettou
Executive Director Diagnostics,
GSK
Heleen Verlinden
Senior Director,
Muna Therapeutics (K5)
Helene Fachim
Clinical Research Manager,
Cure Parkinson's
Inês Santarino
Business Development Manager,
Cyentia Biosource
Isabella Gashaw
Head of Experimental Sciences CRM,
Boehringer Ingelheim
Jacek Lukawy
Innovation Program Director, Translational Medicine Clinical Sciences and Innovation/NIBR,
Novartis
Jan Lukas Robertus
Honorary Associate Professor, Imperial College London and Head of Pathology Department,
Royal Brompton & Harefield NHS Foundation Trust
Janne Martikainen
Professor,
University of Eastern Finland
Jennifer Tucker
Global Head of Regulatory Affairs, Pathology Lab,
Roche Tissue Diagnostics
Jessica Apulei
Scientific Liaison Manager - EMEA,
Hologic Diagenode
Johan Luthman
Executive Vice President & Head R&D ,
Lundbeck
Karthikeyan Devaraju
Sr Scientist,
Cerba Research
Kathrin Heinzmann
Senior Biomarker Scientist,
Cancer Research UK
Kathrin Schlueter
Medical Affairs Manager,
BD
Kedar Natarajan
Professor,
Ashoka University
Krzysztof Kolmus
Principal Scientist,
Ingenix
Maciej Cabanski
Vice President Biomarkers and CDx,
Monte Rosa Therapeutics
Magda Meissner
Consultant Medical Oncologist, Clinical Liquid Biopsy Lead,
Cardiff University
Maham Ansari
Senior Director, IVD Regulatory,
Precision for Medicine
Marie-Christine Bakker
MD-Researcher in Medical Oncology,
UMC Utrecht
Megan O’Shaughnessy
Scientific Affairs Specialist,
ICON
Michael Rebhan
Associate Director,
Novartis
Michal Rosen Zvi
Head of AI for Drug Discovery and Translational Medicine,
Merck
Mirella El Khoury
Senior Field Application Scientist,
Quanterix
Miro Venturi
Chief Executive Officer,
DIAMANTE Healthcare Consulting
Nina Linder
Founder,
Foundation Medicine
Nina Skorytchenko
Chief Executive Officer,
Avenna
Oskar Smrzka
CEO/CSO,
Ablevia biotech GmbH
Özlem Akilli
Director Department of Spatial Biology and Cellular Dynamics,
TRON Translational Oncology Mainz
Paolo Paganetti
Head of Clinical & Laboratory,
Tivenix SA
Patrick Weber
Sales Solution Specialist,
Leica Microsystems, Inc.
Paul Workman
Harrap Professor of Pharmacology and Therapeutics,
The Institute of Cancer Research, London
Petra Kukkaro
Global Biomarker Diagnostic Director,
Novartis
Philip Beer
Chief Scientific Officer,
Step Pharma
Pim French
Professor Molecular Biology of Gliomas,
Erasmus MC
Priyanka Dutta Passecker
Chief Business Officer,
CellPly
Rachel Agoglia
Manager, Global Pharma Applications & Bioinformatics,
Mission Bio
Raif Yuecel
Director, Centre for Life Science Technologies,
University of Exeter
Régis Villet
VP, Commercial Strategy and Medical Innovation,
Synexa Life Sciences
Rene Kubiak
Global Head Early Development & Non-Clinical Biostatistics,
Sanofi
Safia Agueni
Co-Founder,
Healthseed
Sam Cooper
Director Data/ML,
Engitix
Serena Bologna
Principal scientist,
FoRx Therapeutics
Simon Höllerer
Data Scientist,
Novartis
Stefanie Engler
Lab Manager,
University of Zurich
Sujana Sivapatham
Application Scientist,
Arcoris Bio
Susan Greenfield
Chief Executive Officer and Founder,
Neuro-Bio Ltd
Svetlana Mukhina
Director Global Regulatory Affairs, CDx,
Merck Healthcare KGaA
Tatjana Crnogorac-Jurcevic
Professor of Molecular Pathology and Biomarkers,
Barts Cancer Institute, Queen Mary University of London
Taylor Jensen
Vice President, Head of Science Enterprise Oncology,
Labcorp
Thom Reuvers
Chief Operating Officer,
Methylomics BV
Tomas Dias
Chief Scientific Officer,
Mursla Bio
Torbjørn Furuseth
Chief Executive Officer & Co-Founder,
DoMore Diagnostics
Tuc Ahmad
Proteomics| Precision medicine | Bioinformatics Specialist | Customer success developer |Project management enthusiast,
Merck KGaA
Ujjwal Mukund Mahajan
Associate Professor,
National Institute of Pharmaceutical Education and Research (NIPER)
Vasudev Kantae
Associate Director,
AstraZeneca
Vihanga Pahalawatta
Director,
AbbVie

2027 Programme by numbers

25+

Speakers

31+

Sessions

31+

Hours of content

How it connects

Biomarkers & CDx focuses on clinical translation and treatment-linked diagnostic testing. It works hand in hand with the other three programmes: new biomarker candidates from omics, pathology and data science need validated tests before they can inform clinical decisions. 

Frequently Asked Questions

Which biomarkers will reach patients, and what will it take?
The program puts patient impact at the center, with a dedicated track on Biomarkers for Clinical Trials & Personalized Patient Treatment. Sessions cover how to identify clinically actionable biomarkers, test their effectiveness and turn promising discoveries into clinical decisions.
How are IVDR regulations shaping precision medicine?
The Companion Diagnostics & Regulations track looks at how IVDR is shaping companion diagnostic development, clinical trial requirements and implementation, covering compliance, assay validation and NGS-based companion diagnostics. The panel IVDR Regulations & Their Impact discusses what comes next.
Which technologies will have the biggest impact on biomarker analysis?
Sessions span genomics, single-cell and spatial technologies, proteomics, mass spectrometry, flow cytometry and metabolomics, with dedicated discussions on proteomics and the future of liquid biopsy, and on how AI and machine learning strengthen discovery and patient stratification.
Who should attend the Biomarkers & CDx programme?

Translational and clinical biomarker leads, CDx developers, regulatory and market access teams, diagnostics companies, clinicians, clinical trial experts and biomarker analysis teams.

When and where is the Biomarkers & CDx programme at Precision Medicine Europe?
30 November to 1 December 2027, at Congress Centre Basel.

Be part of the conversations shaping
the future of medicine.

30 November - 01 December 2027
Congress Centre Basel, Basel, Switzerland

Spatial Multi-Omics 2026 Agenda at a Glance

DAY ONE 

Track 2: Emerging Multi-Omics Platforms and Applications: Genomics & Transcriptomics 
Track 3: Spatial Biology for Therapeutic Discovery & Development (Oncology & Immunology) 

DAY TWO 

Track 1: Emerging Multi-Omics Platforms and Applications: Proteomics, Epigenomics & Metabolomics 
Track 2: Spatial Biology for Therapeutic Discovery & Development
NGOUS Conference Brochure

Decision 1

Sentence describing Decision 1

Decision 2

Sentence describing Decision 2